No Data
No Data
Trump Reportedly Weighing a Move to Cut U.S. Drug Prices to International Levels
US Recession 'Countdown' Has Begun As Trump Tariffs Push Odds To 45%, Goldman Sachs Warns
Cantor Analyst rarely criticized the USA Secretary of Health, stating that "misguided decisions will backfire on the government's reputation," causing the Biotechnology Sector to plummet.
The financial services institution Cantor Fitzgerald's Biotechnology Analysts Josh Schimmer and Eric Schmidt rarely publicly criticized the leadership of USA Health Secretary Kennedy.
Heard on the Street: Biotech Investors Rush for the Exits After FDA Official Resigns -- WSJ
Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
WHO to Shed Jobs and Slash Budget by a Fifth Amid U.S. Funding Cuts: Reuters